Effect of allopurinol drug use on GFR and proteinuria in patients with renal transplant recipients (ADOPTR study)

• Published in: Transplant immunology Vol. 72; p. 101560
• Main Authors: Usalan, Özlem, Şahin, Ahmet Ziya, Özdemir, Orhan, Cingöz, Mukaddes, Usalan, Celalettin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-06-2022
• Subjects: Albuminuria; Allopurinol; GFR; GFR; Allopurinol; Albuminuria
• ISSN: 0966-3274; 1878-5492
• DOI: 10.1016/j.trim.2022.101560

Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. However, there is no data about the effect of lowering uric acid level on renal functions and proteinuria in renal transplant recipients. This study aimed to investigate the effect of allopurinol treatment on renal functions in renal transplant recipients (RTR).
A total of 245 patients with renal transplantation were included in this randomized, placebo-controlled study. Patients were randomized to receive either placebo (121 patients) or 300 mg/day allopurinol (124 patients). We have examined uric acid, urinary protein creatinin ratio, MDRD (the modification of diet in renal diseases) and CRP (C-reactive protein) before and 24 weeks after treatment in both group.
In the allopurinol group, the mean serum uric acid levels, eGFR (estimated glomerular filtration rate), and creatinine urinary albumin creatinin ratio (UACR) significantly improved (p < 0.001). Also uric acid level was positively correlated with the UACR (r = 0,645 p < 0.001) and negatively correlated with MDRD (r = −0,387 p < 0.05) in allopurinol treatment group. A statistically significant increase in CRP level was observed (p < 0,05) in plasebo group. Multivariate regression analysis showed that uric acid was positively correlated with UACR (r = 0,473, β = 0.021, p = 0.002) and negatively correlated with MDRD (r = −0554 β = 0.016, P = 0.001) in allopurinol treatment RTR.
Urate, a salt of uric acid, is lowered by allopurinol treatment resulting in improved eGFR and decreased proteinuria, when compared to the placebo group. Therefore, we suggest that allopurinol therapy should be part of the management of kidney transplant patients with normal kidney function. Long-term follow-up studies will be useful in revealing the effect of uric acid management on kidney functions and proteinuria.
•Hyperuricemia is associated with the development of renal diseases.•Allopurinol treatment improves eGFR in Kidney Transplant Recipients.•Allopurinol treatment reduces proteinuria in Kidney Transplant Recipients.